Sam's News — health — 2026-08-12¶
Health Policy¶
7 Trump administration to end Medicaid funding for gender-affirming care for transgender minors¶
The Trump administration plans to cease federal Medicaid funding for certain gender-affirming medical treatments for transgender minors.
Sources: STAT News RSS
7 WHO critiques Trump administration vaccine schedule overhaul¶
The WHO criticized an executive order by the president of the United States that seeks to reduce childhood vaccinations and replace combination vaccines with single-pathogen shots, calling the policy scientifically unfounded and politically motivated. The order is based on the disproven claim that vaccines cause autism.
- Executive order signed Monday August 12, 2026, targets MMR and combination vaccines
- Based on disproven autism-vaccine link; WHO: vaccines are safe and do not cause autism
- Proposed changes would make U.S. an outlier, similar to Denmark's lower vaccination rates
- Delaying or separating vaccine doses unnecessarily leaves children unprotected
- WHO Director-General Tedros: policy should be guided by science, not politics
Sources: STAT News AI Web Searched
Health¶
7 Neurocrine Biosciences Prader-Willi Drug Linked to Patient Deaths¶
A newly approved Neurocrine Biosciences drug for the rare genetic disorder Prader-Willi syndrome may be tied to a series of patient deaths, according to medical experts.
Sources: STAT News RSS
7 Ozempic-like drugs may reduce addiction cravings by targeting brain's 'craving center'¶
GLP-1 drugs like Ozempic and Wegovy, originally developed for diabetes and weight loss, appear to reduce cravings for alcohol and addictive substances by acting on the lateral septum, a brain region connecting memory and reward. Human studies confirm reduced alcohol consumption; animal studies show reduced use of cocaine, amphetamines, opiates, and nicotine.
- GLP-1 drugs reduce cravings for alcohol, cocaine, amphetamines, opiates, and nicotine
- Mechanism operates through lateral septum, a brain region densely packed with GLP-1 receptors
- Lateral septum acts as neural control point between thinking about rewards and pursuing them
- Could open new therapeutic approaches to addiction treatment
Sources: ScienceDaily AI Web Searched, ScienceDaily — Health RSS, ScienceDaily — Nutrition RSS
6.5 Definium Therapeutics LSD therapy eases anxiety in late-stage trial¶
Definium Therapeutics reported that its LSD-based therapy significantly reduced anxiety symptoms in the first of two pivotal trials for generalized anxiety disorder.
Sources: STAT News RSS
6 Brain electrical rhythm identified for improving deep brain stimulation in Parkinson's treatment¶
Scientists have discovered a distinctive brain network rhythm that drives the effectiveness of deep brain stimulation for Parkinson's disease, enabling more personalized treatment.
Sources: ScienceDaily RSS, ScienceDaily — Health RSS
6 Adult brain's repair capacity exceeds prior scientific understanding through astrocyte mechanisms¶
Researchers discovered that astrocytes—support cells in the brain—actively rebuild damaged cellular networks in adult mice, suggesting stronger self-repair capacity than previously believed.
Sources: ScienceDaily RSS, ScienceDaily — Health RSS
Healthcare¶
7 Cancer patients face longer waits to begin treatment, new study reveals decade-long trend¶
A study of 2.7 million patients conducted by UCLA researchers analyzing data from 2012 to 2023 found that cancer patients across all major types now face longer delays between diagnosis and treatment compared to a decade ago. Possible factors include care complexity, workforce shortages, and pre-authorization requirements.
- 2.7 million patients studied across stage 1–3 cancers
- Analysis covered 2012 to 2023 using National Cancer Database
- Longer delays consistent across all cancer types examined
- Possible factors: care complexity, workforce shortage, pre-authorization requirements
Sources: STAT News AI Web Searched
Policy¶
6.5 President of the United States administration emphasizes faith-based addiction treatment¶
The White House released a new addiction treatment toolkit emphasizing faith and abstinence while de-emphasizing harm reduction strategies.
Sources: STAT News RSS
Biotech¶
6 Top Autoimmune Researcher Georg Schett Launches Biotech Company with Antibody Therapies¶
Boulevard Bio, co-founded by autoimmune researcher Georg Schett, raised $65 million and launched with three autoimmune disease candidates. The lead asset BLVD101, a bispecific antibody for IgA nephropathy, requires only quarterly dosing compared to weekly or monthly alternatives, with favorable phase 1 safety data.
- $65 million funding from Deerfield Management
- BLVD101 targets BAFF and APRIL proteins; dosed every 12 weeks vs. weekly/monthly existing treatments
- Mahesh Karande (ex-Omega, 7-year Novartis) is CEO
- Schett pioneered CAR-T cell therapy in autoimmune disease; company incubated by Deerfield's 3DC unit
Sources: STAT News AI Web Searched, Fierce Biotech AI Web Searched